Loading organizations...
Health-tech company pioneering blood biomarkers for age-related diseases.
GlycanAge offers a biological age test assessing chronic inflammation and immune health. Its product analyzes glycan patterns, carbohydrate structures on proteins, indicating systemic inflammation. This diagnostic provides a precise biological age, distinct from chronological, giving individuals and providers insights into cellular health and potential age-related concerns.
Co-founded by Nikolina Lauc and Professor Gordan Lauc, GlycanAge emerged from decades of research. Professor Lauc, a glycobiology expert, discovered the link between glycan structures, inflammation, and biological aging. This foundational insight, with Nikolina Lauc's leadership, transformed complex lab science into an accessible preventative health tool.
GlycanAge serves individuals optimizing health and professionals using advanced diagnostics. Its vision aims to redefine preventative medicine through precise, personalized biological data. Enabling early detection and proactive inflammation management, GlycanAge empowers users to improve health trajectories, fostering healthier, extended lifespans.
GlycanAge has raised $12.9M across 2 funding rounds.
GlycanAge has raised $12.9M in total across 2 funding rounds.
GlycanAge has raised $12.9M in total across 2 funding rounds.
GlycanAge's investors include Fifth Quarter Ventures, Elina Halatcheva, Malcolm King, Impetus Capital, Kadmos Capital, LAUNCHub Ventures, Lightfield Equity, South Central Ventures, Vesna Deep Tech VC, John Gebeily, Lyuben Belov.
GlycanAge is a biotech company developing a proprietary biological age test that analyzes IgG glycans—complex sugars on antibodies—to measure chronic inflammation and provide a real-time readout of immune health and aging.[2][1][6] It serves individual consumers seeking personalized health insights, longevity research labs, clinics, hospitals, insurers, pharmaceutical firms, and nutraceutical brands, solving the problem of tracking dynamic lifestyle impacts on biological age faster than genetic or epigenetic tests, which enables proactive adjustments to prevent chronic diseases.[1][2][4][6] The company has shown strong growth momentum, achieving 300% year-on-year growth with minimal marketing via its core product, securing a $4.2M seed round in 2023 led by LAUNCHub Ventures and Kadmos Capital, plus a €7.4M raise, grants like $140K from Mubadala’s HUB71 and $220K EU AI funding, and plans for US lab expansion and new tests like MenoAge.[1][3][7]
GlycanAge emerged from decades of research by co-founder Gordan Lauc, a professor who pioneered glycomics—studying glycans' role in inflammation and aging—launching the Human Glycome Project in 2017 and analyzing over 150,000 glycomes at Genos, the world's leading high-throughput glycan lab.[1][2][3] Incorporated in 2016 (or 2020 per some sources) as a Genos spinout, it was co-founded by Gordan Lauc (CSO) and his daughter Nikolina Lauc (CEO), transitioning lab science into a consumer test for biological age via glycan biomarkers.[1][2][3] Early traction came organically with 300% YoY growth on one product, backed by angels like Tim Marbach (Asia Venture Group) and Maud Pasturaud (Atomico), plus grants, marking pivotal shifts toward diagnostics, AI integration, and disease-specific biomarkers.[1][3]
GlycanAge rides the longevity and preventative health trend, positioning glycans as a sensitive, real-time biomarker for inflammaging—the low-grade inflammation driving age-related diseases—amid rising demand for personalized medicine and biological age tracking.[1][2][6] Timing aligns with AI-health intersections (e.g., EU grants for diagnostics-AI bridging) and post-pandemic focus on proactive wellness, favoring market forces like aging populations and insurer interest in outcomes-based care.[1][2] It influences the ecosystem by fostering glycomics adoption via research partnerships, building the world's largest glycan-health dataset for AI diagnostics/therapeutics, and expanding into clinical practice, potentially standardizing inflammation monitoring like HbA1c for diabetes.[2][4]
GlycanAge is poised to scale its glycan platform into mainstream diagnostics, with near-term US lab setup, B2B integrations, and specialized tests like MenoAge driving revenue amid 300% historical growth.[3][2] Trends like AI-biomarker fusion, regulatory pushes for clinical validation, and longevity market expansion (e.g., chronic disease indications) will shape its path, evolving it from consumer test to ecosystem leader in precision inflammaging interventions.[2][1] This builds on its seed-fueled momentum, empowering users to outpace chronological aging through actionable glycan insights.
GlycanAge has raised $12.9M across 2 funding rounds. Most recently, it raised $8.7M Other Equity in December 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 18, 2025 | $8.7M Other Equity | Fifth Quarter Ventures | Elina Halatcheva, Malcolm King, Impetus Capital, Kadmos Capital, LAUNCHub Ventures, Lightfield Equity, South Central Ventures, Vesna Deep Tech VC |
| Mar 11, 2024 | $4.2M Seed | John Gebeily, Lyuben Belov |